Drug Landscape ›
Furosemide Injection ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 74
Most-reported reactions
Acute Kidney Injury — 14 reports (18.92%) Condition Aggravated — 10 reports (13.51%) Disseminated Intravascular Coagulation — 7 reports (9.46%) Drug Interaction — 7 reports (9.46%) Hepatic Function Abnormal — 7 reports (9.46%) Blood Urea Increased — 6 reports (8.11%) Diarrhoea — 6 reports (8.11%) Hypokalaemia — 6 reports (8.11%) Renal Impairment — 6 reports (8.11%) Electrocardiogram Qt Prolonged — 5 reports (6.76%)
Source database →
Furosemide Injection in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Furosemide Injection approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Furosemide Injection in United States?
Johannes Grand is the originator. The local marketing authorisation holder may differ — check the official source linked above.